Encompass Health stock
Price history
+18.49% over the period1 year: from $112.79 (November 20, 2025) to $133.65 (November 20, 2026), +18.49%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $133.65 |
| October 30, 2026 | $135.90 |
| September 30, 2026 | $121.49 |
| August 31, 2026 | $120.21 |
| July 31, 2026 | $111.07 |
| June 30, 2026 | $101.08 |
| May 29, 2026 | $105.85 |
| April 30, 2026 | $100.00 |
| March 31, 2026 | $96.73 |
| February 27, 2026 | $107.88 |
| January 30, 2026 | $94.53 |
| December 31, 2025 | $106.14 |
| November 28, 2025 | $116.22 |
| November 20, 2025 | $112.79 |
At a glance
The company
Operates inpatient rehabilitation hospitals across the United States and Puerto Rico, providing specialized therapies and medical care for recovery from major injuries and illnesses
Latest results
Quarter to September 30, 2026 · EPS $1.52 (estimate $1.36)
Dividend
TickerLandia's take on Encompass Health
- Pricier than usual relative to earnings: P/E on the latest fiscal year 24 vs a median of 18 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 21 vs 17 (+26%) in a group of 11.
- Strong point: Market momentum (85/100 in its group). Weak point: Dividend (39/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−7.12% from the 52-week high
Analysts · 13 analysts
Average target$156.08+16.79% vs. price
Buy 13 · Hold 0 · Sell 0
TickerLandia Fingerprint: Encompass Health
Compared with similar companies: very strong momentum.
Financials and price compared with 19 companies in the medical care facilities industry, worldwide. Momentum and risk compared with 888 North American stocks.
Priceaverage57
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 11.0 45 P/E (trailing 12 months) 21.4 53 Forward P/E 19.4 58 Price/book 4.90 68 Price/sales 2.07 61 Profitabilityhigh75
How much it earns on revenue and capital.
Metric Value Position in group ROA 10.1% 92 ROE 25.1% 81 Operating margin 18.4% 66 Gross margin 44.1% 71 Net margin 10.2% 66 Earnings stabilityaverage46
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.1% 34 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 58 Growthhigh61
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +8.90% 66 Earnings growth (year over year) +21.60% 66 Average revenue growth (3 years) +10.92% 50 Financial strengthhigh67
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.79 64 Current ratio 1.09 50 Net debt/EBITDAcounts in reverse: lower means more financial strength 1.91 76 Interest coverage 8.55 76 Dividendlow39
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 12.5% 26 Dividend yield 0.6% 32 Consecutive dividend years 14 years 58 Market momentumvery strong85
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +35.63% 89 1-year return +18.49% 66 Distance from 200-day average +18.12% 93 Relative strength (3 months) +22.23% 91 Risklow25
How much the price swings.
Metric Value Position in group Beta (1 year) 0.00 16 Volatility (60 days) 30.5% 38 Maximum drawdown (12 months) 19.3% 22
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Encompass Health is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Encompass Health's P/E today is 24.1, above the median of its last 10 fiscal years (18.0; between 12.6 and 23.1 from 2016 to 2025). Encompass Health's P/E (trailing 12 months): 21.4, +26% against the median of a group of 11 similar companies (16.9).
Compared with 11 similar companies
| Metric | Encompass Health | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 21.4 | Middle | |
| Forward P/E | 19.4 | Middle | |
| Operating margin | 18.4% | Middle | |
| ROE | 25.1% | High | |
| Debt/equity | 0.79 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Encompass Health. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.61B
Latest quarter · Q3 2026
Net income
$149.9M
Latest quarter · Q3 2026
Quarterly net margin
9.3%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $13.11B
- P/E
- 21.4
- EPS
- $6.25
- Volume
- 911.93K
- Daily trading
- €134.93M
- Dividend yield
- 0.58%
How Encompass Health is changing
All resultsRevenue grew 10.7% a year on average over the last 5 years
Operating margin rose from 12.4% to 17.7%
Free cash flow equal to 78% of net income
Returns
Encompass Health returns with dividends
$1,000 invested in Encompass Health 5 years ago, on November 22, 2021, would be worth $2,800 today with dividends reinvested: +180.05% in total, +22.90% per year. On price alone it would be $2,662 (+166.24%).
| Period | Encompass Health | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +9.85% | −10.40% | $1,098 |
| 6 months | +26.10% | −7.03% | $1,261 |
| Year to date | +25.92% | +0.95% | $1,259 |
| 1 year | +19.37% | +5.68% | $1,194 |
| 3 years | +110.26% | +51.96% | $2,103 |
| 5 years | +180.05% | +47.57% | $2,800 |
| 10 years | +372.35% | +214.37% | $4,723 |
Over the last 6 months it has done better than 71% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Encompass Health: technical analysis
Encompass Health is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 6.2% below its highest close since January 2, 1990 ($142.51, November 10, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 50
- Between 30 and 70
- vs 200-session average
- +18.12%
Support and resistance
Price areas where Encompass Health has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$133.65
- Support$118.22−11.54%8 touches, last on October 20, 2026
- Support$109.27−18.24%7 touches, last on July 31, 2026
- Support$106.15−20.57%4 touches, last on July 14, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.00
- Volatility (60 sessions, annualised)
- 30.5%
- Largest fall in the last year
- −19.29%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Encompass Health: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Encompass Health has been April: +7.14% on average, positive in 28 years out of 37. The weakest has been September: −2.16% on average, positive in 18 years out of 37. November, the current month, has been positive in 25 years out of 36 (+5.22% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.02% | +2.57% | 19 of 36 |
| February | −0.61% | +0.68% | 21 of 37 |
| March | −1.31% | +1.16% | 23 of 37 |
| April | +7.14% | +5.23% | 28 of 37 |
| May | +3.69% | −0.47% | 18 of 37 |
| June | +2.49% | 0.00% | 18 of 37 |
| July | +6.27% | −0.28% | 18 of 37 |
| August | +1.80% | +0.12% | 19 of 37 |
| September | −2.16% | −0.34% | 18 of 37 |
| October | +0.67% | −1.45% | 16 of 37 |
| November | +5.22% | +3.09% | 25 of 36 |
| December | +5.33% | +2.64% | 23 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Encompass Health and its competitors
Inpatient rehabilitation care is the core of the business of Encompass Health Corporation, which runs its facilities across the United States and in Puerto Rico. Patients admitted for rehabilitation after a stroke, a brain or spinal cord injury, cardiac or pulmonary conditions, complex orthopedic problems or an amputation receive therapy supported by medical, nursing and ancillary services, with the aim of regaining mobility, independence and quality of life. Payers include the Medicare program, managed care plans, private insurers, state governments and individual patients.
- Headquarters
- Birmingham, United States
- Employees
- 29,875
- Founded
- 1983
- Chief executive
- Mark Tarr
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Encompass HealthEHC | $13.11B | 18.4% | 21.4 | +26.10% |
| Universal Health ServicesUHS | $10.34B | 10.9% | 7.51 | +9.20% |
| Ensign GroupENSG | $10.29B | 8.8% | 26.2 | −1.09% |
| DavitaDVA | $10.13B | 15.2% | 12.2 | −18.20% |
| Tenet HealthcareTHC | $20.95B | 19.1% | 7.68 | +40.44% |
| HCA HealthcareHCA | $99.34B | 15.3% | 15.8 | +19.89% |
Same industry or related industries, similar size. Compare Encompass Health with its competitors · Full profile
